SBIR/STTR Research Award

SBIR Phase II: Continuous, Scalable Crystallizer for Pharmaceutical Manufacturing

Award identifier 20fda2bec5c4482734cf0e1212e2cb33dd768eae985b517fd790fb1e7542e7bcAwarding agency National Science Foundation

Award amount

$1,250,000

Program and phase

SBIR · Phase II

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
ZAIPUT FLOW TECHNOLOGIES LLC
Proposal award date
2025-06-05
Contract end date
2027-05-31
UEI
J4H2SN6EYA94
Solicitation number
NSF 24-580
Topic code
CT

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to improve a key step used in the >$500-billion market of pharmaceutical manufacturing: purification of active pharmaceutical ingredients (APIs). 90% of all APIs are purified using crystallization, however, the current, mainly batch-based, approaches available have drawbacks from both the commercial and scientific points of view. Current techniques are difficult to scale up, are expensive to maintain and manufacture, and are plagued by inconsistency and lack of uniformity in conditions and results. With the development and commercialization of the Scalable Continuous Crystallizer technology proposed here, the company will address the scalability, cost, and inconsistency issues in order to: 1) speed up the transition to advanced manufacturing approaches (Continuous Manufacturing), 2) facilitate the re-shoring of drug manufacturing, contributing to addressing the national security challenge of American dependence on foreign drug manufacturers, and 3) reduce drug production costs, which will eventually lead to cheaper drugs for the benefit of the entire population. In summary, the commercialization of this technology may increase the adoption of advanced technologies, reduce national security risks, and cut the overall costs of pharmaceutical manufacturing. This SBIR Phase II project proposes to further the development of an innovative continuous crystallization device that is expected to be scalable, provide adequate and effective movement of solids, and provide high-quality crystal products, thus fulfilling an unmet need in the pharmaceutical market and in the technical community. The novel design aims to solve the problem of moving solids (crystals) effectively while providing well-controlled flow characteristics with an approach that is scalable from lab to production. The company’s patent-pending Scalable Continuous Crystallizer technology uses a combination

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

4 SBIR/STTR records share this UEI (2021–2025). Reported award amounts total $3,272,335. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.